IPP Bureau
Zydus completes enrolment for two Phase Ill trials of Desidustat
By IPP Bureau - February 08, 2021
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
By IPP Bureau - February 06, 2021
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr
By IPP Bureau - February 06, 2021
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
By IPP Bureau - February 06, 2021
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
WACKER acquires plasmid DNA Manufacturer Genopis
By IPP Bureau - February 05, 2021
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
DKSH to distribute analytical instruments of NanoFCM in Asia
By IPP Bureau - February 02, 2021
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21
By IPP Bureau - February 01, 2021
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr
By IPP Bureau - February 01, 2021
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
CIPLA Q3 FY21 PAT up to Rs. 748.15 Cr
By IPP Bureau - February 01, 2021
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
Laurus Q3 FY21 revenue up 76%; PAT grows 274%
By IPP Bureau - January 29, 2021
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza reports 12% sales growth in 2020
By IPP Bureau - January 28, 2021
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
By IPP Bureau - January 26, 2021
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Slow recovery in biosimilars for Biocon: ICICI Securities
By IPP Bureau - January 26, 2021
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
By IPP Bureau - January 23, 2021
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Syngene Q3 revenue up 13% to Rs. 585 Cr
By IPP Bureau - January 22, 2021
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
